No summary has been written for this.
YieldMax TSLA Performance & Distribution Target 25 ETF is an actively managed ETF designed to provide current income and indirect exposure to Tesla Inc. through an options-based strategy. The fund creates synthetic exposure to Tesla using long call and short put positions, then sells call spreads to generate recurring weekly distributions while seeking to participate in Tesla-related price movements. It is structured as an income-oriented equity ETF and is used by investors looking for a single-security strategy focused on Tesla’s market performance with a defined distribution target. The fund’s portfolio typically includes option positions and cash-like holdings that support its income generation process. YieldMax TSLA Performance & Distribution Target 25 ETF plays a niche role in the derivatives income segment of the ETF market, combining equity-linked exposure with systematic options management.
The latest articles about TEST.
COMPANY ANNOUNCEMENT NO 51/2026 - September 29, 2026 On August 17, 2026, Royal Unibrew announced a share buy-back program, cf. company announcement no. 44/2026. The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of April 16, 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). The share buy-back program is expected to be realized in the period from August 18, 2026, to Decembe
Key Stats for AbbVie StockCurrent Price: $264. 34Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA approved Juvmo (tavapadon), a once-daily Parkinson’s pill from AbbVie (ABBV), on Friday, September 25, according to Reuters.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about TEST also mention these. Each card shows that asset’s own numbers for the past 24 hours.